Shepherd TG - Search Results

1

Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer.

Cook DP, Galpin KJC, Rodriguez GM, Shakfa N, Wilson-Sanchez J, Echaibi M, Pereira M, Matuszewska K, Haagsma J, Murshed H, Cudmore AO, MacDonald E, Tone A, Shepherd TG, Petrik JJ, Koti M, Vanderhyden BC. Cook DP, et al. Among authors: shepherd tg. Commun Biol. 2023 Nov 13;6(1):1152. doi: 10.1038/s42003-023-05529-z. Commun Biol. 2023. PMID: 37957414 Free PMC article.

2

Gain-of-function p53^R175H blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma.

Haagsma J, Kolendowski B, Buensuceso A, Valdes YR, DiMattia GE, Shepherd TG. Haagsma J, et al. Among authors: shepherd tg. Sci Rep. 2023 Jul 14;13(1):11424. doi: 10.1038/s41598-023-38609-5. Sci Rep. 2023. PMID: 37452087 Free PMC article.

3

Mutant p53 murine oviductal epithelial cells induce progression of high-grade serous carcinoma and are most sensitive to simvastatin therapy in vitro and in vivo.

Pereira M, Glogova A, Haagsma J, Stewart J, Shepherd TG, Petrik J. Pereira M, et al. Among authors: shepherd tg. J Ovarian Res. 2023 Nov 20;16(1):218. doi: 10.1186/s13048-023-01307-x. J Ovarian Res. 2023. PMID: 37986175 Free PMC article.

4

Oncolytic virotherapy for ovarian cancer.

Li S, Tong J, Rahman MM, Shepherd TG, McFadden G. Li S, et al. Among authors: shepherd tg. Oncolytic Virother. 2012 Aug;1:1-21. doi: 10.2147/ov.s31626. Oncolytic Virother. 2012. PMID: 25977900 Free PMC article.

5

Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.

Fernández ML, DiMattia GE, Dawson A, Bamford S, Anderson S, Hennessy BT, Anglesio MS, Shepherd TG, Salamanca C, Hoenisch J, Tinker A, Huntsman DG, Carey MS. Fernández ML, et al. Among authors: shepherd tg. Am J Cancer Res. 2016 Oct 1;6(10):2235-2251. eCollection 2016. Am J Cancer Res. 2016. PMID: 27822414 Free PMC article.

6

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target.

Fernandez ML, Dawson A, Hoenisch J, Kim H, Bamford S, Salamanca C, DiMattia G, Shepherd T, Cremona M, Hennessy B, Anderson S, Volik S, Collins CC, Huntsman DG, Carey MS. Fernandez ML, et al. Cancer Cell Int. 2019 Jan 8;19:10. doi: 10.1186/s12935-019-0725-1. eCollection 2019. Cancer Cell Int. 2019. PMID: 30636931 Free PMC article.

7

Inhibiting ULK1 kinase decreases autophagy and cell viability in high-grade serous ovarian cancer spheroids.

Singha B, Laski J, Ramos Valdés Y, Liu E, DiMattia GE, Shepherd TG. Singha B, et al. Among authors: shepherd tg. Am J Cancer Res. 2020 May 1;10(5):1384-1399. eCollection 2020. Am J Cancer Res. 2020. PMID: 32509386 Free PMC article.

8

Loss of LKB1-NUAK1 signalling enhances NF-κB activity in a spheroid model of high-grade serous ovarian cancer.

Buensuceso A, Fritz JL, Collins O, Valdés YR, Borrelli MJ, DiMattia GE, Shepherd TG. Buensuceso A, et al. Among authors: shepherd tg. Sci Rep. 2022 Feb 22;12(1):3011. doi: 10.1038/s41598-022-06796-2. Sci Rep. 2022. PMID: 35194062 Free PMC article.

9

Principles of dormancy evident in high-grade serous ovarian cancer.

Shepherd TG, Dick FA. Shepherd TG, et al. Cell Div. 2022 Mar 23;17(1):2. doi: 10.1186/s13008-022-00079-y. Cell Div. 2022. PMID: 35321751 Free PMC article. Review.

10

Insights into high-grade serous carcinoma pathobiology using three-dimensional culture model systems.

Tomas E, Shepherd TG. Tomas E, et al. Among authors: shepherd tg. J Ovarian Res. 2023 Apr 11;16(1):70. doi: 10.1186/s13048-023-01145-x. J Ovarian Res. 2023. PMID: 37038202 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

72 results

Search Page